Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Insight Molecular Diagnostics (IMDX) Accumulated Depreciation & Amortization (2016 - 2023)

Insight Molecular Diagnostics' Accumulated Depreciation & Amortization history spans 5 years, with the latest figure at $404000.0 for Q3 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 63.27% to $404000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $404000.0, a 63.27% decrease, with the full-year FY2022 number at $1.5 million, up 87.5% from a year prior.
  • Accumulated Depreciation & Amortization hit $404000.0 in Q3 2023 for Insight Molecular Diagnostics, down from $885000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for IMDX hit a ceiling of $1.5 million in Q4 2022 and a floor of -$4.2 million in Q3 2020.
  • Historically, Accumulated Depreciation & Amortization has averaged -$119437.5 across 5 years, with a median of $320000.0 in 2020.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 331.37% in 2022 and later crashed 63.27% in 2023.
  • Tracing IMDX's Accumulated Depreciation & Amortization over 5 years: stood at -$2.5 million in 2019, then surged by 112.46% to $313000.0 in 2020, then skyrocketed by 155.59% to $800000.0 in 2021, then skyrocketed by 87.5% to $1.5 million in 2022, then plummeted by 73.07% to $404000.0 in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for IMDX at $404000.0 in Q3 2023, $885000.0 in Q2 2023, and $450000.0 in Q1 2023.